Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Abstract Text:

Kazunori Kato,Peter Chu,Satoshi Takahashi,Hirofumi Hamada,Thomas J Kipps,Kazunori Kato,Peter Chu,Satoshi Takahashi,Hirofumi Hamada,Thomas J Kipps,

OBJECTIVE: Chronic lymphocytic leukemia (CLL) B cells from most patients express both membrane-bound CD27 (mCD27) and soluble CD27 (sCD27). Expression of sCD27 inhibits CD27-dependent T-cell or CLL-cell activation mediated by its ligand, CD70. In this study, we evaluated whether protease inhibitors could inhibit the release of sCD27 from CLL cells and enhance T-cell activation mediated by CD27-CD70 interaction. METHODS: CLL cells exposed to hydroxamic acid-based matrix metalloprotease (MMP) inhibitors were evaluated for the release of sCD27 by sandwich enzyme-linked immunosorbent assay and immunoprecipitation. We examined for phenotypic changes in CLL cells treated with MMP inhibitors by flow cytometry and T-cell activation by CLL cells was assessed by [(3)H] thymidine incorporation assay and the production of interferon-gamma. RESULTS: Treatment of CLL cells with MMP inhibitors blocked the release of sCD27 to the culture supernatant. In contrast, a non-hydroxamic acid control compound or inhibitors of other proteases, including serine, cysteine, and aspartyl proteases, were ineffective. Furthermore, CLL cells treated with MMP inhibitors expressed significantly higher levels of accessory molecules, such as CD54, CD80, and CD95. Consistent with such changes, we found that CLL cells treated with MMP inhibitors, but not control treated cells, could stimulate allogeneic and autologous T cells in mixed lymphocyte reactions. CONCLUSION: These data reveal that metalloprotease inhibitors can block production of sCD27, which can interfere with mCD27-CD70 interactions that induce expression of immune costimulatory molecules on CLL B cells. Conceivably, treatment of CLL cells with metalloprotease inhibitors may enhance their potential for stimulating cellular immune recognition of leukemia-associated antigens.

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Publishing Authors By Initials

K Kato,P Chu,S Takahashi,H Hamada,TJ Kipps,K Kato,P Chu,S Takahashi,H Hamada,TJ Kipps,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Experimental hematology

VOLUME: 35

Page Numbers: 434-42

Journal Abbreviation: Exp. Hematol.

ISSN: 0301-472X

DAY: 20

MONTH: Mar

YEAR: 2007

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 402313

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.

AFFILIATION: Division of Hematology/Oncology, Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA. kakazu@sapmed.ac.jp

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Exp Hematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells Related Publications

• Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
• Biology and treatment of chronic lymphocytic leukemia.
• Cellular immune therapy for chronic lymphocytic leukemia.
• Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
• Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells.
• Genomic complexity in chronic lymphocytic leukemia.
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
• Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.
• Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.
• Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
• The isolation in eggs of a new filtrable agent which may be the cause of bovine lumpy skin disease.
• Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
• Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia.
• ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.